CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

8302	Companies
115129	Keywords
55450	Articles
62533	Press releases

Home
Companies
CureVac

BRIEF

published on 04/18/2024 at 13:05, 7 months 3 days ago

CureVac to Announce Q4 and Full-Year 2023 Results on April 24, 2024

Financial Results Conference Call CureVac MRNA Technologies Business Updates
PRESS RELEASE

published on 04/18/2024 at 13:00, 7 months 3 days ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
CureVac to report Q4 and full-year 2023 financial results and business update on April 24, 2024. Conference call and webcast scheduled. Details at www.curevac.com/en/newsroom/events/

Financial Results Conference Call Business Update MRNA Technology CureVac
BRIEF

published on 04/16/2024 at 13:05, 7 months 5 days ago

CureVac and MD Anderson Collaborate on Innovative Cancer Vaccines

MRNA Technology CureVac MD Anderson Cancer Vaccines Biopharmaceutical Collaboration
PRESS RELEASE

published on 04/16/2024 at 13:00, 7 months 5 days ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors

Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF

published on 04/04/2024 at 13:05, 7 months 17 days ago

CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK

GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
PRESS RELEASE

published on 04/04/2024 at 13:00, 7 months 17 days ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile

GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE

published on 11/01/2023 at 13:00, 1 year ago

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE

published on 09/28/2023 at 13:00, 1 year 1 month ago

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE

published on 09/12/2023 at 13:15, 1 year 2 months ago

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE

published on 09/12/2023 at 13:00, 1 year 2 months ago

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

Accesswire

Published on 11/22/2024 at 00:00, 4 hours 25 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 6 hours 20 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 6 hours 35 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 8 hours 10 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 8 hours 15 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 9 hours 24 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 9 hours 49 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 10 hours 27 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 10 hours 34 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 10 hours 34 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 21 hours 27 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 9 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 10 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 10 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 20 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE